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Background: Smart materials capable of responding to external stimuli are noteworthy
candidates in designing drug delivery systems. In many of the recent research, temperature
and pH have been recognized as the main stimulating factors in designing systems for anti-
cancer drugs delivery systems.
Purpose: In this study, thermo and pH-responsive character of a nano-carrier drug delivery
platform based on lysine modiﬁed poly (vinylcaprolactam) hydrogel conjugated with dox-
orubicin was assessed.
Methods: Poly (vinylcaprolactam) cross-linked with poly (ethyleneglycol) diacrylate was
prepared via RAFT polymerization, and the prepared structure was linked with lysine through
ring-opening. The anti-cancer drug doxorubicin, was linked to lysine moiety of the prepared
structure via Schiff-base reaction. The prepared platform was characterized by 1HNMR and FT-
IR, while molecular weight characterization was performed by size exclusion chromatography.
The temperature-responsive activity was evaluated using differential scanning calorimetry and
dynamic light scattering. In vitro release pattern in simulated physiologic pH at 37°C was
compared with acidic pH attributed to tumor site and elevated temperature. The anticancer
efﬁciency of the drug-conjugated structure was evaluated in breast cancer cell line MCF-7 in 24
and 48 h, and cell uptake assay was performed on the same cell line.
Conclusion: According to the results, well-structure deﬁned smart pH and temperature
responsive nano-hydrogel was prepared. The enhanced release rates are observed at acidic
pH and elevated temperature. We have concluded that the doxorubicin-conjugated nanopar-
ticle results in higher cellular uptakes and more cytotoxicity.
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Introduction
During the past decade, nanotechnology has been focused on ﬁnding novel solu-
tions to reduce the side effects of drugs, especially in diseases like cancer.1
Nowadays, nano-sized particles have been recruited as the carrier of therapeutic
agents to deliver them to the speciﬁed target tissues, such as tumor sites.2 Some
types of therapeutics loaded with nanoparticles have been categorized as
nanopharmaceuticals.3 Doxil, as the commercial formulation of nano-liposome of
doxorubicin (DOX), is a chemotherapeutic agent used to treat cancer. It has found a
huge market size and made great beneﬁts for patients traditionally treated with
DOX by reducing common side effects, such as hair loss, heart and tissue damage
and more.4
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The medical application of nanotechnology, which is
recognized in an emerging ﬁeld called nano-medicine, espe-
cially in drug delivery, is under development. Designing an
engineered sustainable nano-structured system that has
complete control over releasing cargo is the golden goal
in drug delivery systems (DDS).5,6 In this regard, smart
materials capable of responding to external stimuli are
noteworthy candidates in DDS engineering and have the
potential to be applied commercially.2,7 These types of
materials are mostly made by the development of smart
and intelligent polymers. The external stimulus is mostly
categorized as chemical and physical; chemical stimuli
consisting of changes in pH8 and ionic strength9 and phy-
sical stimuli including light,10,11 temperature,12 mechanical
forces10, and wavelengths.13 Due to the numerous beneﬁts
acquired in working with smart polymeric systems – includ-
ing sensitivity to stimulus, long-term stabilities, biocompat-
ibility, and high adsorption capacity – their applications are
extensively studied in tissue engineering, gene delivery, and
drug delivery.14 In many of the recent research, temperature
and pH have been recognized as the main stimulating
factors in designing DDS, given the fact that the tempera-
ture of the tumor site is higher than average body tempera-
ture, and their pH is more acidic than the normal cells
(~5.8).8,12
Thermoresponsive polymeric materials could exhibit
two main critical phase transitions in aqueous media at
certain temperatures: the ﬁrst show lower critical solution
temperature (LCST) (immiscible at a temperature higher
than LCST), and the second presents upper critical solu-
tion temperature (UCST) (immiscible at temperature lower
than UCST).15 The hydration and dehydration reactions in
the aqueous system after heating affects the dissolution
process for thermoresponsive materials.16 To have a con-
trolled DDS from a thermoresponsive nano-carrier for
cancer therapy purposes, the LCST should be adjusted to
a temperature higher than the normal body temperature
(>37°C).17 Temperature variation in ﬁghting infections in
most vertebrates is through elevation between 1 and 5
degrees.18 To adjust the temperature in thermoresponsive
polymers the addition of hydrophilic segments could
increase the LCST of well-known types, such as poly(N-
isopropylacrylamide) (PNIPAAm) (LCST~32°C), poly(N,
N-diethylacrylamide) (LCST ranging from 25°C to 32°C)
and cyclic lactam, such as poly(N-vinylcaprolactam)
(PVCL) (LCST ranging from 25°C to 35°C).16,19
PVCL is among the well-known synthetic thermore-
sponsive polymers, which, despite PNIPAAm, do not
produce toxic amide compound under acidic conditions.19
Furthermore, due to the important characteristics including
as hydrophilicity, excellent biocompatibility, stability
against hydrolysis, and smart behavior toward pH and
temperature, it has been widely applied for biomedical
applications. Various types of PVCL-based materials
have been developed such as micelles, gels (i.e., nano
and micro) and hybrids (i.e., core/corona) and investigated
for their pharmaceutical trends in drug/gene delivery.20
Nanogels are recognized as potent carriers in medical
applications.21 Injectable bio-based hydrogels were con-
structed for multi-mode tumor therapy.22
Development in free radical polymerization techni-
ques, like reversible addition fragmentation/RAFT and
atom transfer radical polymerization/ATRP, has enabled
scientists to synthesize a polymeric nano-carrier in sev-
eral forms, including self-assembled, micelles, and
hydrogels.23,24 The RAFT method is recognized as an
ideal and green method that could be applied in the
polymer synthesis with a wide class of monomers, is
also applicable to a less activated monomer (such as
vinylamides) and could be successfully applied to
N-vinylcaprolactam (VCL).19,25
RAFT polymerization has been successfully recruited
in the synthesis of smart thermoresponsive platform with
PVCL. Recently, a physically cross-linked microgel has
been derived from poly(ethylene glycol) (PEG)-b-poly
(VCL-co-vinyl acetate), where chain transfer agent
(CTA) is a functionalized CTA-PEG and efﬁciently serves
as macro RAFT agent.26 Biocompatible nanocapsules
emanated from RAFT copolymerization of VCL and
acrylic acid was developed in a vesicle templating route.27
A sustainable amino-functionalized platform with thermo
and pH sensitivity was prepared from amino-VCL, which
was basically synthesized from cyclic lysine and polymer-
ized in the RAFT process.28 A polymersome nano-formu-
lation made of tannic acid locked-PVCL-b-poly
(N-vinylpyrrolidone) with vesicular morphology was pre-
pared and applied efﬁciently for thermo-triggered DOX
delivery.29 Nano-micellar formulation of PVCL-b-polyca-
prolactone, suitable for drug delivery, was synthesized.30
Furthermore, in an emulsion polymerization microgels of
PVCL cross-linked by PEG diacrylate (PEGDA) was
created.31 A biodegradable DOX delivery system was
also created based on PVCL nanogels.32
Recently, we reported synthesis and application of smart
pH-responsive DOX delivery system based on poly (hydro-
xyethyl methacrylate-co-dimethylaminoethyl methacrylate)
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nano-hydrogel.33 In this study, PVCL as a hydrophilic tem-
perature-sensitive polymer that is well known for biocom-
patibility and complexation capability was selected. PEG, as
an amphiphilic polymer with nontoxic metabolites and FDA
approval was considered as a cross-linker of this system.
L-lysine as a cationic and water soluble amino acid was
selected as PVCL modiﬁer and drug linker agent. DOX, as
one of the most common models of anticancer drugs,
was conjugated to polymeric-supported backbone via a
Schiff-base linkage to obtain pH-responsive release. In a
brief, the preparation of PVCL cross-linked (PEGDA)
hydrogel via RAFT polymerization and then functionaliza-
tion with L-lysine and conjugation via Schiff-base linkage
with DOX as novel thermo and pH-responsive anticancer
delivery system is reported.
Experimental section
Materials and methods
Cyanomethyl N-methyl N-phenyldithiocarbamate,
l-lysine, VCL (98%), α,α-bisisobutyronitrile (AIBN,
98%), PEGDA(Mn 575), 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT), rhodamine
B (Rhod), N-hydroxysuccinimide, and (1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide) (EDC) were bought
from Sigma-Aldrich. AIBN was puriﬁed through recrys-
tallization from methanol, VCL was recrystallized in
benzene and PEGDA puriﬁed through the silica gel col-
umn by washing with dichloromethane and dried under
vacuum before starting the synthesis.1,4-Dioxane (Fluka,
99.5%) was dried using CaCl2, and absolute drying was
accomplished by reﬂuxing in sodium wire and benzophe-
none (0.2% g/L) under nitrogen until the dark blue color
appeared. DOX hydrochloride was purchased from
EBEWE Pharma. MCF-7 breast cancer cell lines were
purchased from Pasteur Institute (Iran). RPMI (Roswell
Park Memorial Institute medium) 1640 from Biosera,
France and fetal bovine serum (FBS) from Shellmax.
Instrument
1HNMR spectra were obtained using a 250 MHz instru-
ment from Bruker Avance DPX Company, using D2O as
the solvent. Fourier transform infrared spectra of the
synthesized polymers were recorded on a Bruker
(VERTEX70). Dynamic light scattering (DLS) was carried
out by using Malvern Nano and zeta (ξ) potential deter-
mined by zeta sizer (Microtrac USA). Transmission
electron microscopy (TEM) images were recorded by
Philips CM 10 instrument via grid preparation. Grids
were prepared by dropping a solution of 500 µg/mL of
PVCL-Lys. After taking images at room temperature, the
grid was incubated at 42°C and image taking was repeated.
Cryo TEM was performed by FEI Titan Krios. The sam-
ples were vitriﬁed (plunge frozen into liquid ethane) on
Quantifoil R2/2 Cu 300 mesh grids. Biotrak Elisa plate
reader was applied for UV-Vis records. The dialysis tubing
from Sigma with 32 mm width and MWCO 12,400. Size
exclusion chromatography (SEC) was performed with
Agilent 1260 high-performance liquid chromatography
(HPLC). The samples were lyophilized by Christ, Alpha,
2–4-ld plus/Germany freeze dryer. Microtube shaking was
performed in Bioer, mixing block MB-102/China instru-
ment. UV absorbance was recorded by CECIL CE7250
instrument. Olympus BX61/Japan Fluorescent microscope
was applied for observing slides and for PVCL-Rhod
particles, ﬁlter with mirror unit of U-MWLB3, dichrom
mirror of DM505, excitation ﬁlter of BP460-495, and
barrier ﬁlter BA510lF was applied. Flowcytometry was
operated by BD FACSCalibur ﬂowcytometer/BD USA.
Synthesis of nano-hydrogel (PVCL-PEG)
The experimental procedure employed in this study was a
RAFT polymerization.34 The details are explained here,
brieﬂy. Initially, VCL (9 mmol), cyanomethyl N-methyl
N-phenyl dithiocarbamate (0.045 mmol) as RAFT agent,
AIBN (3 mg, 0.0182 mmol) as initiator and PEGDA
(0.27 mmol) as a cross-linker were dissolved in dried
dioxane (5 mL). In the next step, the mixture was placed
in a Schlenk reaction tube and degassed under nitrogen
and freeze-thawed ﬁve times. Then, the tube was sealed
and stirred at 90°C for 48 hrs. Afterward, the reaction
was chilled and washed with dried n-hexane three times.
Finally, the product was dried by using freeze-drying
machine for 48 hrs.
Synthesis of lysine-modiﬁed PVCL-PEG
(PVCL-Lys)
Synthesized PVCL-PEG (0.1 g) and L-lysine (20 mg)
were dissolved in 20 mL deionized (DI) water and stirred
for 24 hrs at room temperature. Then, to remove excess
and unreacted lysine, the mixture dialyzed in DI water for
24 hrs and ﬁnally freeze-dried.
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DOX conjugation to PVCL-LYs
(PVCL-DOX)
DOX conjugation was accomplished through Schiff-base
reaction and prepared using the following method. Brieﬂy,
PVCL-Lys (80 mg), DOX (8 mg), and triethylamine
(Et3N) (8 µL) were dissolved in methanol (20 cc) and
stirred for 48 hrs at room temperature in a dark location.
Afterward, to remove unconjugated DOX, the mixture was
dialyzed in DI water for 6 hrs and then freeze-dried.
Rhodamine conjugation to Pvcl-Lys
(PVCL-Rhod)
To have ﬂuorescence-tagged particles, rhodamine B
(Rhod) was conjugated to PVCL-Lys. To do so, Rhod
(0.06 mmole) was activated in aqueous solution (4 mL)
of N-hydroxysuccinimide (0.12 mmole) and EDC (0.06
mmole) for 4 hrs at 40°C. After that, PVCL-Lys (40 mg)
and Et3N (0.14 mmole) were admixed with activated
Rhod, and the mixture stirred for 24 hrs at the same
temperature. Afterward, to remove unconjugated Rhod,
the mixture dialyzed in DI water for 6 hrs and then
freeze-dried.
Size exclusion chromatography
To deﬁne the molecular weight (MW), SEC was per-
formed on HPLC system with a Tsk gel G 3000 SWXL
column. Epidermal growth factor with 6 KDa was utilized
as the standard sample. The instrument was equipped with
UV/Vis detector and detected samples at 200 nm. Fifty
microliters aqueous solution (1 mg/mL) of PVCL-Rhod
was injected onto the column. Elution buffer was 9 g/L
NaH2PO4, 9 g/L Na2HPO4, and orthophosphoric acid 85%
was applied to adjust pH of aqueous solution in 6.5. The
adjusted ﬂow rate was 0.5 mL/min.
Determination of DOX and Rhod content
To deﬁne the amount of DOX conjugated to PVCL, sam-
ples containing 100 µg/mL of PVCL-DOX were acidiﬁed
by hydrochloride acid (pH=1.2, 2 mL). Then, they were
stirred for 48 hrs at 40°C, afterward the absorbance at 478
nm was recorded using Elisa plate reader. Finally, absor-
bance of the samples was subtracted from the absorbance
of PVCL-Lys solution with similar concentration. The
same procedure was performed to determine Rhod conju-
gation percent of PVCL-Rhod. Finally, the Rhod amount
was determined using standard calibration curve of Rhod.
Release proﬁle of PVCL-DOX
Release proﬁle experiment assessment was performed by
considering two factors, pH (5 and 7.4) and temperature
(37°C and 40°C). The set of four experiments were per-
formed in microtubes (2 mL). Samples of 100 µg/mL
PVCL-DOX in physiological-simulated pH of 7.4 with
two temperatures of 37°C and 40°C in PBS medium, and
simulated tumor pH of 5 with two temperatures of 37°C
and 40°C in HCL adjusted pH were prepared. The proﬁle
of release was measured within different time intervals of
0.5, 1, 2, 3, 6, 12, 24, 48, 72 hrs by detecting the absor-
bance of free DOX using UV/Vis spectrophotometer at
478 nm and subtracting from the absorbance of the solu-
tion of PVCL-Lys with similar concentration.
In vitro cellular cytotoxicity assessment
To investigate cytotoxic effects, MTT assay was used
according to the reported procedure.35 First, the MCF-7
cells were cultured in RPMI 1640-supplemented medium
with 10% FBS at 37°C (5% CO2) incubator. Brieﬂy,
10×104 cells in 100 μL of completed medium were seeded
on each well of 96-well microplates. After 24 hrs, different
concentrations of DOX and PVCL-Lys in various concen-
trations (0.5, 1.25, 2.5, 3.75, 5 µg/mL) and PVCL-DOX
concentrations (10, 25,50, 75, 100 µg/mL) corresponding
to DOX concentrations of (0.5, 1.25, 2.5, 3.75, 5 µg/mL)
were added to the wells in triplicate. The cells were
incubated further for 24 and 48 hrs, and the medium was
then recharged with 100 μL of diluted MTT solution.
Following 4 hrs of incubation and MTT solution aspira-
tion, 150 μL of dimethyl sulfoxide was added to the wells.
Finally, the absorption of each well was measured after 30
mins by spectrophotometry in the wavelength of 492 nm,
and then 50% inhibitory concentration (IC50) was deter-
mined by Curve Expert 1.4 software. The statistical ana-
lysis was performed by analysis of variance method.
Uptake assay using ﬂuorescence microscopy
For uptake assay using ﬂuorescence microscopy, 3×105
cells in 2 mL of completed medium were seeded on sterile
glass slides already put into each well of six well micro-
plates. After 24 hrs incubation for attaching the cells to the
slides, different concentrations of DOX (0.3, 0.6, and 1.2
ppm), PVCL-DOX (15, 30, and 60 ppm) and PVCL-Rhod
(15, 30, and 60 ppm) were added to the wells. After 24 and
48 hrs, the glass slides were removed from each well, one
drop of glycerol on the glass slides was added; then, a new
Farjadian et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
International Journal of Nanomedicine 2019:146904
glass slide was placed on the back on the slides, which
were observed by ﬂuorescence microscope.
Uptake assay using ﬂow cytometry assay
For uptake assay using ﬂow cytometry method, 5×104
cells in 500 μL of completed medium were cultured on
the each well of 24 well microplates. After 24 hrs, DOX
(0.3, 0.6, and 1.2 µg/mL), PVCL-DOX (15, 30, and
60 µg/mL) and the same concentration of PVCL-Rhod
were added to the wells. The cells were incubated for 4,
24, and 48 hrs, then harvested and transferred to ﬂow
cytometry tubes.
Results
Synthesis, structural characterization, and
MWdetermination
PVCL is a promising candidate as a thermoresponsive
carrier for drug delivery purposes. In this work, novel
lysine-modiﬁed hydrogel was synthesized, characterized
and successfully recruited for DOX delivery. The synthetic
route based on RAFT polymerization technique is illu-
strated in Figure 1.
VCL is copolymerized with PEGDA, which acts as a
cross-linker via RAFT polymerization technique. CTA acts
as the main precursor in RAFT reactions, and for n-viny-
lamide monomers, such as VCL, cyanomethyl N-methyl
N-phenyl dithiocarbamate is an appropriate candidate.36
The initiator (i.e., AIBN) starts the polymerization, and
the dormant chains are capped with dithiocarbamate end
group, which can be activated in the second run of poly-
merization and is useful in preparation of block copoly-
mers with controlled chains length.37 PEGDA, as an
amphiphilic cross-linker with PEG chains, was selected
to develop the hydrogel property and biocompatibility.
Herein, to provide a speciﬁc site for the conjugation of
drug to synthesized structure of PVCL-PEG, L-lysine was
conjugated. To characterize the structure of PVCL-PEG
and PVCL-Lys, 1HNMR spectroscopy was performed
(Figure 2). The characteristic peaks of PVCL and PEG
appeared in their spectra, as shown in Figure 2. The degree
of polymerization was determined by 1HNMR spectro-
scopy through determining the integration of CTA char-
acteristic peak while compared with characteristic peak of
PVCL and PEG.
In this regard, dithiocarbamate moiety (N-CH3) at end
group of each polymeric chain was conﬁrmed by the peak at
4.83 µg/mL and hydrogen of methane group of PVCL from
(CH2-N) at 4–4.5 µg/mL and methylene groups of PEG (-O-
CH2-CH2-O-) at 3.8 µg/mL. The integrated area ratio of
CTA/PVCL/PEG is about 1/40/1.5, close to feed ratio
amount (1:47:3), and the MW is found to be 6652 D. In the
next step, L-lysine was added to open PVCL ring and start
branches functionalized with lysine. The 1HNMR spectrum
(Figure 2) is shown and, in comparison to PVCL-PEG, the
peak multiplexing of PVCL occurs in the region of 1.1–1.9,
2–2.5, and 3.18–3.3 µg/mL, while a characteristic band of
lysine moiety (COOH-CH-NH) appears at 4.5 µg/mL. The
amount of CTA/Lysine-modiﬁed branches are about 1/5,
indicating that 5 out of 40 PVCL rings were opened. After
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Figure 1 Schematic and structural illustration of the synthetic pathway in preparation of PVCL-DOX nano-hydrogel.
Abbreviations: PVCL, poly(N-vinylcaprolactam); DOX, doxorubicin.
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that, the PVCL-Lys were reacted with DOX to have (PVCL-
DOX) through Schiff-base reaction.
Furthermore, the structures of synthesized nanogels
were characterized by FT-IR spectroscopy (Figure S1).
As depicted in the spectrum, the absorption at 1420 and
1470 cm−1 can be attributed to amide I and II of PVCL.
The C–H stretching vibration appears at 2937 and
2910 cm−1. The characteristic band of C–O appears at
1070–1200 cm−1, related to PEG group of cross-linker.
Also, after PVCL-PEG was modiﬁed with lysine, the
N–H vibrational absorption peak of ammonium chloride
group appears at 1718 cm−1 due to successful modiﬁcation
with lysine.
To conﬁrm the accurate MW of the prepared sample,
SEC was carried out. As the HPLC detector was UV/Vis,
the PVCL-Lys sample was tagged with ﬂuorescent dye
(Rhod) to create PVCL-Rhod. The MW was determined
to be 6035 D, which is close to 1HNMR measurement.
Phase transition behavior
The phase transition behaviors of synthesized materials
were determined by calorimetric measurements, as they
are dependent on temperature (Figure S2). The DSC
curves show the phase transition changes of solid materials
of PVCL-PEG and PVCL-Lys at temperatures of 32°C and
35°C, respectively. This provides evidence that the LCST
changes at higher temperatures when PVCL-PEG is mod-
iﬁed with lysine.
However, the phase transition behavior was monitored
by particle size changes via recording DLS as a function of
temperature (Figure S3). Within a temperature range of
(30–45°C), the Z-average diameters of PVCL-PEG and
PVCL-Lys in aqueous solution were monitored and within
transition temperature, the sizes dropped dramatically. The
decrease in sizes is observed for PVCl-PEG and
PVCL-Lys at about 35°C and 38°C, respectively, which
were in correlation with what was observed in test tubes
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through mild temperature changes that caused the medium
to become turbid. There were about 3°C differences
between the phase transition temperatures recorded by
DSC and DLS. This observation could be rationalized by
successful hydrogen bonding, which induces an increase in
phase transition temperature in an aqueous solution. On
the other hand, there was no change in LCST while DOX
was conjugated to PVCL-Lys due to the low concentration
of DOX.
Morphology observation
To observe size changes of the prepared materials in
aqueous solution, TEM images were recorded below and
above LCST temperatures of PVCL-Lys (Figure 3). The
nanogel formation was vivid in TEM images below and
above LCST. In the room temperature, particles are
formed in sizes around 50 nm, and, with short sonica-
tion, nanoparticles become immiscible in aqueous solu-
tion (Figure 7A). At 42°C, nano-hydrogels lose their
hydrophobic interaction with water molecules and form
nanocapsules; this dehydration process is observable in
TEM images. The size of nanocapsules’ length ranges
between 45 and 72 nm, with a width around 18 nm
(Figure 3B).
To have better observation of PVCL-Lys without
aggregation which was apparent in Figure 3A, the
PVCL-Lys sample was scanned by Cryo TEM
(Figure 4). The separate nano-hydrogel particles showed
to have sizes less than 20 nm.
DOX conjugation and release proﬁle
Taking into account the aforementioned sections, the
PVCL-Lys can serve as a platform for drug delivery
system. The zeta-potential of this system is measured at
2.4 mV. The amine group of lysine as nucleophilic site
could be applied for the conjugation of drugs with
electrophilic groups. DOX was selected to evaluate the
application of this platform in drug delivery. The con-
jugation of DOX was carried out through Schiff-base
reaction (Figure 1). Schiff-base bond would provide pH
sensitivity to this delivery system.38 After chemical
reaction, the synthesized material (PVCL-DOX) was
dialyzed to remove physically attached particles. The
amount of DOX was determined by UV-Vis spectro-
scopy to be 5% in PVCL-DOX. The synthesized mate-
rial (PVCL-DOX), which has characteristics similar to
PVCL-Lys, acts as a thermo and pH-responsive plat-
form for DOX delivery. The release proﬁle was
42 nm
48 nm
150 nm
18 nm
300 nm
72 nm
54 nm
45 nm
A B
Figure 3 TEM image of PVCL-Lys at (A) room temperature (<LCST) and (B) at 42°C (>LCST).
Abbreviations: TEM, transmission electro microscopy; PVCL, poly(N-vinylcaprolactam); LCST, lower critical solution temperature.
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determined in the simulated medium of physiological
pH and temperature (7.4°C and 37°C) and tumor site
with pH and temperature changes (5°C and 40°C,
respectively) (Figure 5). The lowest and moderate
releases are observed at 37°C in pH of 7.4 within the
time interval of 72 hrs of about 37% and changes
occurred to about 50% while pH reduced to 5, which
made Schiff-base bond susceptible to hydrolysis. The
highest amounts of release (80%) is recorded at 40°C
and pH of 5 within 72 hrs, which could be considered
as proof of pH and thermoresponsive properties of
PVCL-DOX (Figure 5).
In vitro toxicity evaluation
In an efﬁcient anticancer delivery system, the biocompat-
ibility of the nano-carrier and the toxicity of drug-loaded
nano-carrier are of great importance. To evaluate the bio-
compatibility of PVCL-Lys and the anticancer efﬁciency
of PVCL-DOX, the MTT assay was performed on breast
cancer cell line/MCF-7. The cultured medium of MCF-7
was treated with DOX, PVCL-Lys, and PVCL-DOX in
various concentrations within two time intervals of 24 and
48 hrs (Figure 6). The results reveal that PVCL-DOX is an
effective anticancer agent with a toxicity level comparable
to free DOX (and even more so after 24 hrs); however, the
anti-proliferation activity of PVCL-Lys demonstrates a
minor toxicity. The results of PVCL-DOX inhibition
could be more effective if the temperature as a factor of
sensitivity was evaluated. The amount of IC50 is calculated
for DOX and PVCL-DOX to be 13.5 and 6.72 µg/mL in
24 hrs, and 0.6 and 1.49 µg/mL in 48 hrs, respectively.
Uptake assay using ﬂuorescence
microscopy and ﬂow cytometry
Identifying the cellular entrance pathway of drug-loaded
nanoparticles is an important way to understand their
efﬁciency in drug delivery. Size, shape, charge, functional
groups, and the presence of targeting ligands on nanopar-
ticles are some of the conﬁrmed inﬂuential factors in the
cellular entrance of nanoparticles. Dye-tagging technique
was used to check the cellular accumulation of PVCL-
DOX and PVCL-Lys. The ﬂuorescence microscopy
images were taken after 24 and 48 hrs treatment of
MCF-7 cells with DOX, PVCL-DOX, and PVCL-Rhod
(Figure 7).
Cellular penetration of DOX was observed after 24 hrs
incubation of cells by its low (III) and high (I) concentra-
tions (Figure 6). On the other hand, due to cellular death,
no signiﬁcant ﬂuorescence is observed after 48 hrs incuba-
tion of cells with a high concentration of DOX (I)
(Figure 7A and D). The results indicate the ability of the
PVCL-DOX in cellular death induction, even after the
treatment of cells by its low concentration (III).
In order to eliminate the effect of DOX in cellular
death and examine whether the PVCL-Lys could penetrate
into cells, images from PVCL-Rhod were taken in the
same concentration as PVCL-DOX (Figure 7C and F).
Based on the observations, after 24 hrs incubation of
cells with PVCL-Rhod, nano-hydrogels are dispersed
only in the cytoplasm of cells. However, after 48 hrs, the
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ﬂuorescence dye is observed in both cytoplasm and
nucleus of the cells (Figure 7F).
In further analysis, the presence of DOX, PVCL-DOX,
and PVCL-Rhod in the MCF-7 cells was checked quanti-
tatively by ﬂow cytometry. MCF-7 cells were treated with
DOX, PVCL-DOX, and PVCL-Rhod, and after 4, 24, and
48 hrs, the cells were analyzed. The obtained ﬂow cyto-
metry histograms are shown in Figure 7. The mean ﬂuor-
escent intensity (MFI) of the MCF-7 cells in each
experiment is shown in the histograms. The MFI results
reveal the easy and high penetrations of DOX molecules
into the cells (Figure 8A). A high ﬂuorescence intensity is
observed in the cells treated with DOX after 24 hrs incu-
bation. However, the ﬂuorescence intensity decreases after
48 hrs incubation due to the cellular death. Fluorescence
intensity of the cells treated with a low concentration of
PVCL-DOX (15 µg/mL) is not high after 4 hrs incubation,
indicating the lower cellular penetration of these particles
(Figure 8B).
However, promising results are observed after 24 and
48 hrs of incubation, where the PVCL-DOX nanoparticles
are able to induce more cellular death (lower MFIs).
PVCL-Rhod particles are able to penetrate into the cells
roughly after 4 hrs. A concentration-dependent increase in
MFI of the PVCL-Rhod treated cells is observed after
24 hrs incubation. However, after 48 hrs incubation,
there is a decrease in the MFI, which could be a result of
cellular death (Figure 8C).
Discussion
A novel type of lysine-modiﬁed nano-hydrogel based on
PVCL with PEGDA cross-linker was synthesized and
characterized. RAFT polymerization technique, as a
powerful method in controlled living polymerization,
was utilized. As an important feature of controlled radi-
cal polymerization technique is that the crosslinking
could be controlled while monomer and cross-linker
(divinyl compound) are copolymerized simultaneously.21
1HNMR and SEC results show the expected MWs are
close to feed ratio amounts. Lysine could act as a
modifying agent of thermo-sensitivity and offers several
other advantages such as being non toxic agent, increas-
ing positive charge, improving the interaction of the
nano-carrier with cell membrane ligands and providing
functional groups (i.e., NH2 and COOH) for the con-
jugation of therapeutic agents, all of which could make
the structure appropriate for drug and gene delivery.39
DSC and SEC prove a thermo responsive feature of the
synthesized particles and lysine modiﬁcation, which
could successfully tune the LCST in aqueous solution
up to 38°C. As prepared, the material could disperse in
aqueous solution and make stable and transparent med-
ium. Upon encountering LCST, stable colloidal solution
is formed. Based on DLS and TEM results, the PVCL-
Lys form hydro-colloidal water miscible microparticles.
Morphology and sizes of these particles can change in
temperature higher than LCST (≥38°C), and nanoparti-
cles with sizes less than 200 nm in DLS is observed
(Figure 3 SI). TEM images also show nano-capsule
formation with less than 100 nm length. The engineered
nanoparticles possess the expected and essential criteria,
which are necessary for a nano-carrier for therapeutic
agent delivery.
In this work, delivery of DOX was evaluated. The
presence of lysine more speciﬁcally, its amine groups in
the polymeric matrix of nanoparticles provides special
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sites for DOX conjugation via pH-responsive Schiff-
base linkages. The developed platform shows pH- and
temperature-responsive features, which are suitable for
delivery of drug molecules to tumor sites. According to
the internalization route of nanoparticles, temperature
would be the primary stimulus in cell entrance of nano-
particles. The systems would realize pH changes
gradually from early endosomes processes.5 The results
of release assessment show the highest release percent
(~80%) at 40°C and pH of 5, where the release was
directly in response to temperature and pH sensitivity. In
vitro cellular evaluation in breast cancer cell line/MCF-7
exhibits a high toxicity by PVCL-DOX; comparable to
free DOX and even more after 24 hrs. However, the
A DOX 24h
I I
IIII II
IIIIIIIII
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II
III
I
II
III
I
II
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I
B PVCL-DOX after 24h C PVCL-Rhod after 24h
D DOX after 24h E PVCL-DOX after 48h F PVCL-Rhod after 48h
Figure 7 MCF-7 cellular uptake assessment; images of confocal laser scanning microscopy after 24 and 48 hrs treatment of (A andD) DOXwith three different concentrations (I:
1.2 µg/mL, II: 0.6 µg/mL, III:0.3 µg/mL), (B and E) PVCL-DOX and (C and F) PVCL-Rhod with three different concentrations (I: 60 µg/mL, II: 30 µg/mL, III: 15 µg/mL).
Abbreviations: DOX, doxorubicin; PVCL, poly(N-vinylcaprolactam).
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temperature factor could not be involved in in vitro
cellular analysis, and all tests were performed at 37°C.
It is expected that the PVCL-DOX would be more
efﬁcient in vivo due to the higher temperature of the
tumor sites (40°C). Cellular uptake assay via ﬂuores-
cence microscopy demonstrates a higher toxicity induc-
tion by PVCL-DOX when compared to free DOX, even
in 24 hrs. It is assumed that the crossing of PVCL-DOX
through cell membrane bypasses the apically located
efﬂux transporter, such as pg-protein and facilitated the
cellular accumulation of DOX. After the evaluation of
the PVCL-Rhod, it appears that nanoparticles could
accumulate in cytoplasm in ﬁrst 24 hrs and then dis-
tributed in nucleus, too. The ﬂow cytometry results
demonstrate a gradual cell penetration process of the
nanoparticles, compared to the free DOX molecules (in
4 hrs). However, the induction of cellular death by
PVCL-DOX increases during the time (in 24 and 48
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hrs). This result could support to the time dependency of
cellular entrance by PVCL-DOX. Based on this obser-
vation, compared to the mechanism of cellular entrance
by free DOX molecules, it seems that the cellular
entrance of PVCL-DOX nanoparticles is occurring via
cellular membrane penetration. According to the sug-
gested cellular route of internalization of nanoparticles
which encompasses endocytosis, temperature would be
the ﬁrst stimulus that DDS encounters in tumor site.5
The PVCL-Lys has the potential to be considered as a
potent carrier in therapeutic delivery. Gene delivery of the
aforementioned particles is also under investigation and
will be the topic of our next report. It is anticipated that
PVCL-Lys being degraded in cellular medium due to
PEGDA hydrolysis, and both cargo delivery and the clear-
ance route of carrier will be facilitated. In this experiment,
we introduced and evaluated the PVCL-Rhod as dye-
tagged particle, which could be efﬁciently applied in the
determination of some biological phenomenon pathways.
In vivo investigation of the aforementioned platform will
be considered in future studies.
Conclusion
Herein, a novel temperature and pH-responsive DOX
delivery system based on hydrogel was developed. The
primary structure was based on PVCL cross-linked with
PEGDA modiﬁed with lysine, and in the ﬁnal step, DOX
was conjugated. Successful RAFT polymerization techni-
que was performed for the skeletal synthesis of nano-
hydrogel resulting in network formation with MW of
about 6022 Da. The thermoresponsive properties were
evaluated and lysine-modiﬁed structure (PVCL-Lys)
proved to be tuned up to 38°C. TEM images show that
particles that have swelled below LCST could form sepa-
rated nanoparticles at a temperature higher than LCST.
Conjugation of DOX to PVCL-Lys took place via pH-
responsive Schiff-base linkage. The release proﬁle showed
that about 80% release could be obtained at 40°C and pH
of 5, which is in accordance with simulated condition of
cancer site. In vitro cellular studies on MCF-7 cell line
showed a high potential of PVCL-DOX in killing cells.
The uptake assay indicates that nanoparticles’ entrance
route to cells might be through cellular membrane pene-
tration. PVCL-DOX acts more efﬁciently than free DOX
and has a potential to be considered as an anti cancer
agent.
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